Apeiron | apeiron-biologics.com

Contact
APEIRON Biologics AG
Campus-Vienna-Biocenter 5
1030 Vienna
Austria
Phone +43(1)8656577

Fax +43(1)8656577-800

E-Mail apeiron@apeiron-biologics.com
Where we are
APEIRON Biologics AG auf GoogleMaps
Meet us at
- ASCO 2013,
  May 31-June 4, 2013 Chicago, IL, USA
- SITC,
  November 6-10, 2013 Washington DC, USA
- BIO Europe 2013,
  November 6-10, 2013 Vienna, Austria
Legal Info
- UID: ATU61205939
  FN: 242223k Handelsgericht Wien
  Information lt. ECG und Mediengesetz.
Media
Logos
CMYK / 300dpi / B=50mm
CMYK / 300dpi / B=150mm
CMYK / 300dpi / B=150mm
CMYK
RGB / 72dpi / B=300px
RGB
Images
Hans Loibner, CEO

Manfred Schuster, COO

Lukas Kadawy, CFO
Knowledge
Literature
- ACE2 (APN01)
- - ACE2 review
  - Hamming I et al. The emerging role of ACE2 in physiology and disease. J Pathol 212: 1-11 (2007)
  - ACE2 and ARDS
  - G Santacruz JF et al. Update in ARDS management: recent randomized controlled trials that changed our practice. Cleve Clin J Med. 73, 217 (2006)
    
    Rubenfeld GD et al., Incidence and Outcomes of Acute Lung Injury. New England Journal of Medicine 16:1685 (2005)
    
    Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112-116 (2005).
    
    Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11, 875-879 (2005).
    
    Kuba K, Penninger J et al. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol. 6, 271-6 (2006)
    
    Imai Y, Kuba K, Penninger J. The renin-angiotensin system in acute respiratory distress syndrome. Drug Discovery Today: Disease Mechanisms: Immuno-disorders and autoimmunity Vol. 3, No. 2 (2006)
  - ACE2 and cardiovascular disease
  - Crackower, M.A. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828 (2002)
    
    Danilczyk, U. & Penninger, J.M. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 98, 463-471 (2006)
    
    Sarkissian SD et al. ACE2: A novel therapeutic target for cardiovascular diseases. Progress in Biophysics and Molecular Biology 91, 163-98 (2006)
    
    Ferrario CM. Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7): An Evolving Story in Cardiovascular Regulation. Hypertension 47: 515-521 (2006)
    
    Burrell LM et al. Myocardial infarction increases ACE2 expression in rat and humans. European Heart Journal 26: 369-375 (2005)
    
    Goulter A et al. ACE2 gene expression is up-regulated in the human failing heart. BMC Medicine 2:19 (2004)
    
    Huentelman M et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90.5, 783-790 (2005)
    
    Yamamoto, K. et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47, 718-726 (2006)
  - ACE2 and kidney disease
  - Ingelfinger, J.R. ACE2: a new target for prevention of diabetic nephropathy? J Am Soc Nephrol 17, 2957-2959 (2006)
    
    Danilczyk, U. & Penninger, J.M. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 98, 463-471 (2006)
    
    Ye, M. et al. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17, 3067-3075 (2006)
    
    Soler MJ et al. ACE2 inhibition worsens glomular injury associated with increased ACE expression in streptozotocin-induced diabetic mice. Kidney International advance online publication, 20 June 2007
    
    Reich H et al. Glomerular and Tubular Expression of ACE2 in Type 2 Diabetic Patients with Diabetic Nephropathy, submitted.
  - APN01 publications based on Apeiron's work
  - Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice.
    Hepatology 2009
    
    Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Convertng Enzyme 2. Prevention of Angiotensin II-Dependent Hypertension.
    Hypertension 2009
    
    Human recombinant angiotensin converting enzyme 2 reduces the progression of diabetic nephropathy.
    Diabetes 2010
    
    Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets.
    Crit Care Med 2009
    
    Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction Circulation. 2010
- Cbl-b (APN401/411)
- - Bachmaier, K. et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403, 211-216 (2000).
  - Jeon, M.S. et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21, 167-177 (2004).
  - Krawczyk, C.M. et al. Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b. J Immunol 174, 1472-1478 (2005).
- Superoxide Dismutase (APN201)
- - Riedl CR et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol. 2005 Oct;48(4):656-61
  - Braun E et al. Experimental design for in vitro skin penetration study of liposomal superoxide dismutase. J Pharm Biomed Anal. 2006 Mar 18;40(5):1187-97. Epub 2005 Oct 25.
  - Vorauer-Uhl K et al. Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation. Eur J Pharm Sci. 2001 Aug;14(1):63-7.
  - Riedl CR et al. Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease. Eur Urol. 2001 Sep;40(3):343-8; discussion 348-9.
- Neuroblastoma (APN311/301)
- - Yu AL et al. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. N Engl J Med 2010;363:1324-34.
  - Zeng Y et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Molecular Immunology 42 (2005) 1311–1319.
  - Handgretinger R et al. A Phase I Study of Human/Mouse Chimeric Anti-ganglioside GD2 Antibody ch14.18 in Patients with Neuroblastoma. Eur J Cancer, Vol.31A, No.2, pp.261-67, 1995.
  - Shusterman et al. Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children’s Oncology Group (COG) Phase II Study. J Clin Oncol. 2010 Nov 20;28(33):4969-75.
  - Navid F et al. Anti-GD2 Antibody Therapy for GD2-Expressing Tumors. Current Cancer Drug Targets, 2010, 10, 200-209.

Phone	+43(1)8656577
Fax	+43(1)8656577-800
E-Mail	apeiron@apeiron-biologics.com